Human antibody molecules for IL-13
There are described recombinant VH and VL domains of human antibodies that bind IL-13. A series of proteins characterised by three CDR in each VH/VL are described. Preferably the molecules are single chain Fv or antibody molecules. Nucleic acids expressing the VH and VL domains are selected from pha...
Gespeichert in:
Hauptverfasser: | , , , |
---|---|
Format: | Patent |
Sprache: | eng ; fre ; ger |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | MONK, PHILLIP, DAVID JERMUTUS, LUTZ SHORROCK, CELIA, PATRICIA MINTER, RALPH, RAYMOND |
description | There are described recombinant VH and VL domains of human antibodies that bind IL-13. A series of proteins characterised by three CDR in each VH/VL are described. Preferably the molecules are single chain Fv or antibody molecules. Nucleic acids expressing the VH and VL domains are selected from phage display libraries. Neutralization potency of the resulting scFv's was tested in TF proliferation assays. The fragments and antibodies showed efficacy for IL-13 binding in murine models of pulmonary inflammation, the primate (cynomolgus) model of dermal allergy, IgE release from B cells and histamine potentiation in Ca2+ signalling in smooth muscle. Mice transgenic for human IL-13 antibodies and epitope mapping studies are also described. It is envisaged that the anti 11-13 reagents may be used to treat asthma, atopic dermatitis, allergic rhinitis, fibrosis, IBS, or Hodgkin's lymphoma. |
format | Patent |
fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP2292660A3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP2292660A3</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP2292660A33</originalsourceid><addsrcrecordid>eNrjZFDyKM1NzFNIzCvJTMpPqVTIzc9JTS7NSS1WSMsvUvD00TU05mFgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8a4BRkaWRmZmBo7GxkQoAQAVkSS0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Human antibody molecules for IL-13</title><source>esp@cenet</source><creator>MONK, PHILLIP, DAVID ; JERMUTUS, LUTZ ; SHORROCK, CELIA, PATRICIA ; MINTER, RALPH, RAYMOND</creator><creatorcontrib>MONK, PHILLIP, DAVID ; JERMUTUS, LUTZ ; SHORROCK, CELIA, PATRICIA ; MINTER, RALPH, RAYMOND</creatorcontrib><description>There are described recombinant VH and VL domains of human antibodies that bind IL-13. A series of proteins characterised by three CDR in each VH/VL are described. Preferably the molecules are single chain Fv or antibody molecules. Nucleic acids expressing the VH and VL domains are selected from phage display libraries. Neutralization potency of the resulting scFv's was tested in TF proliferation assays. The fragments and antibodies showed efficacy for IL-13 binding in murine models of pulmonary inflammation, the primate (cynomolgus) model of dermal allergy, IgE release from B cells and histamine potentiation in Ca2+ signalling in smooth muscle. Mice transgenic for human IL-13 antibodies and epitope mapping studies are also described. It is envisaged that the anti 11-13 reagents may be used to treat asthma, atopic dermatitis, allergic rhinitis, fibrosis, IBS, or Hodgkin's lymphoma.</description><language>eng ; fre ; ger</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2011</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20111012&DB=EPODOC&CC=EP&NR=2292660A3$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20111012&DB=EPODOC&CC=EP&NR=2292660A3$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>MONK, PHILLIP, DAVID</creatorcontrib><creatorcontrib>JERMUTUS, LUTZ</creatorcontrib><creatorcontrib>SHORROCK, CELIA, PATRICIA</creatorcontrib><creatorcontrib>MINTER, RALPH, RAYMOND</creatorcontrib><title>Human antibody molecules for IL-13</title><description>There are described recombinant VH and VL domains of human antibodies that bind IL-13. A series of proteins characterised by three CDR in each VH/VL are described. Preferably the molecules are single chain Fv or antibody molecules. Nucleic acids expressing the VH and VL domains are selected from phage display libraries. Neutralization potency of the resulting scFv's was tested in TF proliferation assays. The fragments and antibodies showed efficacy for IL-13 binding in murine models of pulmonary inflammation, the primate (cynomolgus) model of dermal allergy, IgE release from B cells and histamine potentiation in Ca2+ signalling in smooth muscle. Mice transgenic for human IL-13 antibodies and epitope mapping studies are also described. It is envisaged that the anti 11-13 reagents may be used to treat asthma, atopic dermatitis, allergic rhinitis, fibrosis, IBS, or Hodgkin's lymphoma.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2011</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZFDyKM1NzFNIzCvJTMpPqVTIzc9JTS7NSS1WSMsvUvD00TU05mFgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8a4BRkaWRmZmBo7GxkQoAQAVkSS0</recordid><startdate>20111012</startdate><enddate>20111012</enddate><creator>MONK, PHILLIP, DAVID</creator><creator>JERMUTUS, LUTZ</creator><creator>SHORROCK, CELIA, PATRICIA</creator><creator>MINTER, RALPH, RAYMOND</creator><scope>EVB</scope></search><sort><creationdate>20111012</creationdate><title>Human antibody molecules for IL-13</title><author>MONK, PHILLIP, DAVID ; JERMUTUS, LUTZ ; SHORROCK, CELIA, PATRICIA ; MINTER, RALPH, RAYMOND</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP2292660A33</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2011</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>MONK, PHILLIP, DAVID</creatorcontrib><creatorcontrib>JERMUTUS, LUTZ</creatorcontrib><creatorcontrib>SHORROCK, CELIA, PATRICIA</creatorcontrib><creatorcontrib>MINTER, RALPH, RAYMOND</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>MONK, PHILLIP, DAVID</au><au>JERMUTUS, LUTZ</au><au>SHORROCK, CELIA, PATRICIA</au><au>MINTER, RALPH, RAYMOND</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Human antibody molecules for IL-13</title><date>2011-10-12</date><risdate>2011</risdate><abstract>There are described recombinant VH and VL domains of human antibodies that bind IL-13. A series of proteins characterised by three CDR in each VH/VL are described. Preferably the molecules are single chain Fv or antibody molecules. Nucleic acids expressing the VH and VL domains are selected from phage display libraries. Neutralization potency of the resulting scFv's was tested in TF proliferation assays. The fragments and antibodies showed efficacy for IL-13 binding in murine models of pulmonary inflammation, the primate (cynomolgus) model of dermal allergy, IgE release from B cells and histamine potentiation in Ca2+ signalling in smooth muscle. Mice transgenic for human IL-13 antibodies and epitope mapping studies are also described. It is envisaged that the anti 11-13 reagents may be used to treat asthma, atopic dermatitis, allergic rhinitis, fibrosis, IBS, or Hodgkin's lymphoma.</abstract><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | eng ; fre ; ger |
recordid | cdi_epo_espacenet_EP2292660A3 |
source | esp@cenet |
subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
title | Human antibody molecules for IL-13 |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T00%3A23%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=MONK,%20PHILLIP,%20DAVID&rft.date=2011-10-12&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP2292660A3%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |